- Home
- IMTX vs ARCT Comparison
IMTX vs ARCT Comparison
Compare IMTX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- ARCT
- Stock Information
- Founded
- IMTX N/A
- ARCT 2013
- Country
- IMTX Germany
- ARCT United States
- Employees
- IMTX N/A
- ARCT N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- ARCT Health Care
- Exchange
- IMTX Nasdaq
- ARCT Nasdaq
- Market Cap
- IMTX 514.2M
- ARCT 444.5M
- IPO Year
- IMTX N/A
- ARCT N/A
- Fundamental
- Price
- IMTX $4.26
- ARCT $10.53
- Analyst Decision
- IMTX Strong Buy
- ARCT Strong Buy
- Analyst Count
- IMTX 4
- ARCT 7
- Target Price
- IMTX $16.67
- ARCT $57.80
- AVG Volume (30 Days)
- IMTX 849.5K
- ARCT 462.9K
- Earning Date
- IMTX 05-13-2025
- ARCT 05-07-2025
- Dividend Yield
- IMTX N/A
- ARCT N/A
- EPS Growth
- IMTX N/A
- ARCT N/A
- EPS
- IMTX 0.14
- ARCT N/A
- Revenue
- IMTX $161,336,577.00
- ARCT $152,310,000.00
- Revenue This Year
- IMTX N/A
- ARCT N/A
- Revenue Next Year
- IMTX $18.80
- ARCT $39.21
- P/E Ratio
- IMTX $29.39
- ARCT N/A
- Revenue Growth
- IMTX 188.60
- ARCT N/A
- 52 Week Low
- IMTX $3.30
- ARCT $8.04
- 52 Week High
- IMTX $13.77
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- IMTX 48.54
- ARCT 43.14
- Support Level
- IMTX $4.03
- ARCT $10.07
- Resistance Level
- IMTX $4.48
- ARCT $11.00
- Average True Range (ATR)
- IMTX 0.39
- ARCT 0.88
- MACD
- IMTX 0.05
- ARCT 0.26
- Stochastic Oscillator
- IMTX 75.00
- ARCT 77.81
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.